| Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain S Agarwal, R Sane, R Oberoi, JR Ohlfest, WF Elmquist Expert reviews in molecular medicine 13, e17, 2011 | 320 | 2011 |
| Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up S Agarwal, A MS Hartz, W F Elmquist, B Bauer Current pharmaceutical design 17 (26), 2793-2802, 2011 | 286 | 2011 |
| Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux S Agarwal, R Sane, JL Gallardo, JR Ohlfest, WF Elmquist Journal of Pharmacology and Experimental Therapeutics 334 (1), 147-155, 2010 | 266 | 2010 |
| P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib Y Chen, S Agarwal, NM Shaik, C Chen, Z Yang, WF Elmquist Journal of Pharmacology and Experimental Therapeutics 330 (3), 956-963, 2009 | 243 | 2009 |
| Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma S Agarwal, P Manchanda, MA Vogelbaum, JR Ohlfest, WF Elmquist Drug Metabolism and Disposition 41 (1), 33-39, 2013 | 195 | 2013 |
| The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain S Agarwal, R Sane, JR Ohlfest, WF Elmquist Journal of Pharmacology and Experimental Therapeutics 336 (1), 223-233, 2011 | 187 | 2011 |
| Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp … S Agarwal, Y Uchida, RK Mittapalli, R Sane, T Terasaki, WF Elmquist Drug metabolism and disposition 40 (6), 1164-1169, 2012 | 155 | 2012 |
| Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents S Agarwal, RK Mittapalli, DM Zellmer, JL Gallardo, R Donelson, C Seiler, ... Molecular cancer therapeutics 11 (10), 2183-2192, 2012 | 113 | 2012 |
| Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design N Giri, S Agarwal, N Shaik, G Pan, Y Chen, WF Elmquist Drug Metabolism and Disposition 37 (3), 560-570, 2009 | 98 | 2009 |
| Pharmacokinetics and pharmacodynamics of the small interfering ribonucleic acid, givosiran, in patients with acute hepatic porphyria S Agarwal, AR Simon, V Goel, BA Habtemariam, VA Clausen, JB Kim, ... Clinical Pharmacology & Therapeutics 108 (1), 63-72, 2020 | 89 | 2020 |
| Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood–brain barrier: a case study examining sorafenib efflux clearance S Agarwal, WF Elmquist Molecular pharmaceutics 9 (3), 678-684, 2012 | 81 | 2012 |
| Brain distribution and bioavailability of elacridar after different routes of administration in the mouse R Sane, S Agarwal, WF Elmquist Drug Metabolism and Disposition 40 (8), 1612-1619, 2012 | 72 | 2012 |
| Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors AZ Dudek, A Raza, M Chi, M Singhal, R Oberoi, RK Mittapalli, S Agarwal, ... Clinical genitourinary cancer 11 (2), 155-160, 2013 | 53 | 2013 |
| Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system R Sane, S Agarwal, RK Mittapalli, WF Elmquist Journal of Pharmacology and Experimental Therapeutics 345 (1), 111-124, 2013 | 51 | 2013 |
| Brain distribution of cediranib is limited by active efflux at the blood-brain barrier T Wang, S Agarwal, WF Elmquist Journal of Pharmacology and Experimental Therapeutics 341 (2), 386-395, 2012 | 49 | 2012 |
| Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate L Li, S Agarwal, WF Elmquist Drug metabolism and disposition 41 (3), 659-667, 2013 | 42 | 2013 |
| Pharmacokinetic and drug–drug interaction profiles of the combination of tezacaftor/ivacaftor V Garg, J Shen, C Li, S Agarwal, A Gebre, S Robertson, J Huang, L Han, ... Clinical and translational science 12 (3), 267-275, 2019 | 40 | 2019 |
| Intra-operative point-of-procedure delineation of oral cancer margins using optical coherence tomography SP Sunny, S Agarwal, BL James, E Heidari, A Muralidharan, V Yadav, ... Oral oncology 92, 12-19, 2019 | 38 | 2019 |
| The nonclinical disposition and pharmacokinetic/pharmacodynamic properties of N-Acetylgalactosamine–conjugated small interfering RNA are highly predictable and build confidence … R McDougall, D Ramsden, S Agarwal, S Agarwal, K Aluri, M Arciprete, ... Drug Metabolism and Disposition 50 (6), 781-797, 2022 | 37 | 2022 |
| Dose-related reductions in blood pressure with a RNA interference (RNAi) therapeutic targeting angiotensinogen in hypertensive patients: interim results from a first-in-human … SA Huang, J Taubel, G Fiore, P Dewland, GL Bakris, AS Desai, Y Cheng, ... Circulation 142 (Suppl_3), A14387-A14387, 2020 | 23 | 2020 |
Rajendar K MittapalliClinical Pharmacology Lead, Pfizer Inc.Verified email at pfizer.com
